Screening and Monitoring for Infectious Complications When Immunosuppressive Agents Are Studied in the Treatment of Autoimmune Disorders.
Open Access
- 26 June 2014
- journal article
- guideline
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 4 (3), 198-204
- https://doi.org/10.1093/jpids/piu055
Abstract
Significant progress has been made in the development, investigation, and clinical application of immunosuppressive agents to treat a variety of autoimmune disorders. The expansion of clinical applications of these new agents requires the performance of large multicenter clinical trials. These large clinical trials are particularly important as one considers these agents for the treatment of type 1 diabetes, which although autoimmune in its pathogenesis, is not classically treated as an autoimmune disorder. Although these agents hold promise for amelioration or cure of this disease, they have the potential to facilitate infectious complications. There are limited data regarding the prospective assessment of infectious risks with these agents in trials of this nature. Pediatric subjects may be at greater risk due to the higher likelihood of primary infection. A subgroup of experts associated with TrialNet (a National Institutes of Health [NIH]-funded Type 1 diabetes mellitus research network) with expertise in infectious diseases, immunology, and diagnostics developed an approach for screening and monitoring of immunosuppression-associated infections for prospective use in clinical trials. The goals of these recommendations are to provide a structured approach to monitor for infections, to identify specific laboratory testing and surveillance methods, and to consider therapies for treatment of these potential complications. Prospective evaluations of these infectious risks allow for greater scientific rigor in the evaluation of risk, which must be balanced with the potential benefits of these therapies. Our experience supports an important role for investigators with expertise in infections in immunocompromised individuals in protocol development of immunosuppressive trials in type 1diabetes and potentially other autoimmune diseases.Keywords
This publication has 30 references indexed in Scilit:
- Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myelomaJournal of Medical Virology, 2013
- Introduction: Infections in Solid Organ TransplantationAmerican Journal of Transplantation, 2013
- Epstein-Barr and Other Herpesvirus Infections in Patients With Early Onset Type 1 Diabetes Treated With Daclizumab and Mycophenolate MofetilClinical Infectious Diseases, 2012
- Longitudinal analysis of frequency and reactivity of epstein–barr virus‐specific T lymphocytes and their association with intermittent viral reactivationJournal of Medical Virology, 2011
- Seroprotective Titers against 2009 H1N1 Influenza A Virus after Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation RecipientsTransplantation and Cellular Therapy, 2011
- Hepatitis B Virus Reactivation following Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2009
- The Burden of Respiratory Syncytial Virus Infection in Young ChildrenNew England Journal of Medicine, 2009
- Persistent and Relapsing Babesiosis in Immunocompromised PatientsClinical Infectious Diseases, 2008
- Selective Lymphopenia and Opportunistic Infections in Neuroendocrine Tumor Patients Receiving TemozolomideCancer Investigation, 2007
- Prevention of Cytomegalovirus Disease in Recipients of Solid-Organ TransplantsClinical Infectious Diseases, 2001